Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CELSA, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.368
AS - Asia 2.980
EU - Europa 2.963
SA - Sud America 508
AF - Africa 81
OC - Oceania 9
Totale 10.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.218
RU - Federazione Russa 1.086
SG - Singapore 1.051
IT - Italia 736
CN - Cina 590
BR - Brasile 391
HK - Hong Kong 318
VN - Vietnam 307
BD - Bangladesh 305
DE - Germania 263
PL - Polonia 220
FR - Francia 158
FI - Finlandia 130
GB - Regno Unito 105
JP - Giappone 102
CA - Canada 82
IN - India 63
AT - Austria 44
AR - Argentina 42
TR - Turchia 36
ES - Italia 35
IE - Irlanda 34
SE - Svezia 31
KR - Corea 30
MX - Messico 30
NL - Olanda 30
IQ - Iraq 29
EC - Ecuador 23
ZA - Sudafrica 20
VE - Venezuela 17
CI - Costa d'Avorio 16
UZ - Uzbekistan 15
PK - Pakistan 14
PY - Paraguay 14
RO - Romania 14
SA - Arabia Saudita 14
BE - Belgio 12
ID - Indonesia 12
MY - Malesia 12
UA - Ucraina 12
EG - Egitto 11
PH - Filippine 11
LT - Lituania 10
JM - Giamaica 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
CR - Costa Rica 8
DZ - Algeria 8
CH - Svizzera 7
CL - Cile 7
CO - Colombia 7
JO - Giordania 7
KZ - Kazakistan 7
IL - Israele 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
GE - Georgia 5
NP - Nepal 5
CZ - Repubblica Ceca 4
GT - Guatemala 4
HN - Honduras 4
KE - Kenya 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
TH - Thailandia 4
TW - Taiwan 4
BS - Bahamas 3
HR - Croazia 3
HU - Ungheria 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
UY - Uruguay 3
GR - Grecia 2
GY - Guiana 2
LB - Libano 2
LV - Lettonia 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BG - Bulgaria 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GL - Groenlandia 1
IR - Iran 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
Totale 10.900
Salva come PNG Salva come JPEG
Città #
Singapore 696
Ashburn 664
San Jose 513
Hong Kong 297
Chandler 277
Fairfield 212
Zgierz 192
Moscow 171
New York 164
Palermo 153
Los Angeles 131
Council Bluffs 124
Ho Chi Minh City 108
Beijing 107
Lauterbourg 97
Tokyo 94
Hefei 84
Santa Clara 84
Houston 83
Woodbridge 83
Helsinki 81
Rome 75
Seattle 71
Ann Arbor 68
Wilmington 68
Hanoi 67
The Dalles 67
Altamura 63
Dallas 62
Medford 58
Buffalo 50
Milan 46
Cambridge 45
Frankfurt am Main 43
Lappeenranta 43
Orem 41
Boardman 40
Lawrence 36
Princeton 36
Nuremberg 35
Dublin 34
São Paulo 33
London 30
Ludwigshafen am Rhein 28
Bremen 27
Chicago 26
Des Moines 26
Montreal 25
Warsaw 25
Vienna 22
San Diego 21
Brooklyn 19
Denver 18
Atlanta 17
Chennai 17
Da Nang 17
Toronto 17
Abidjan 16
Florence 15
Phoenix 15
Poplar 15
Columbus 14
Johannesburg 14
Tashkent 14
Ankara 13
Haiphong 13
Naples 13
Redondo Beach 13
Stockholm 13
Bologna 12
West Jordan 12
Amsterdam 11
Biên Hòa 11
Washington 11
Belo Horizonte 10
Dhaka 10
Guangzhou 10
Rio de Janeiro 10
San Francisco 10
Turin 10
Baghdad 9
Central 9
Hải Dương 9
Mexico City 9
Paris 9
Porto Alegre 9
Quito 9
Brasília 8
Brussels 8
Cordova 8
Falkenstein 8
Gangbuk-gu 8
Istanbul 8
Krefeld 8
Munich 8
Pune 8
Salt Lake City 8
Tianjin 8
Venice 8
Changsha 7
Totale 6.282
Salva come PNG Salva come JPEG
Nome #
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 298
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 262
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 248
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 205
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 198
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 197
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 193
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 193
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 191
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 181
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 176
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 172
Systemic therapies for hepatocellular carcinoma: The present and the future 166
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 165
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 160
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 160
Biochemical biomarkers of NAFLD/NASH 158
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 156
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 154
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 154
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 150
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 149
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 148
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 148
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 141
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 140
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 134
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 133
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 133
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 132
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 132
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 129
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 128
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 127
Biliary complications after liver transplantation: current perspectives and future strategies 127
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 126
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 125
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis 124
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 123
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 123
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis 118
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 118
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 116
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 113
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 112
Reply 110
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 108
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 104
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 103
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 103
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 103
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 103
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 102
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 101
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 101
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 101
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 101
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 101
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 101
Reply 100
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 100
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 94
The Application of Large Language Models in Gastroenterology: A Review of the Literature 93
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 91
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 90
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 89
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 88
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 87
Hepatocellular carcinoma in people living with HIV 86
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 86
Identification of clinical phenotypes and related survival in patients with large hccs 84
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 81
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 79
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 78
Patients’ radiation exposure during TIPS creation in a high-volume referral hospital 78
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 78
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma 76
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 75
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives 75
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 71
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 70
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 69
The price and value of therapeutic synergy in liver cancer 69
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab 67
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 66
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis 65
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 61
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 57
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 57
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 55
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 52
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 52
Reply to: “irLI or not irLI: That is the question” 51
Expert opinion vs. meta-analysis: To be or not to be? 49
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 48
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 48
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events 48
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 47
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT) 46
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 42
Totale 11.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.668
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.668
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/20251.768 35 125 217 131 31 140 146 82 96 193 229 343
2025/20266.950 417 165 393 679 611 991 858 850 561 461 503 461
2026/2027149 149 0 0 0 0 0 0 0 0 0 0 0
Totale 11.554